Drug Profile
Research programme: ocular therapeutics - Plex Pharmaceuticals
Alternative Names: CAP 1160Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Plex Pharmaceuticals
- Class Eye disorder therapies; Small molecules
- Mechanism of Action HSP27 heat-shock protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Myopia; Presbyopia
- No development reported Cataracts
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Cataracts in USA (Topical)
- 10 Jan 2022 Preclinical trial in Presbyopia in USA (unspecified route) (Plex Pharmaceuticals pipeline, January 2022)
- 10 Jan 2022 Preclinical trials in Myopia in USA (unspecified route) (Plex Pharmaceuticals pipeline, January 2022)